Zentalis Pharmaceuticals Llc
$ 6.61
49.55%
10 Apr - close price
- Market Cap 468,854,000 USD
- Current Price $ 6.61
- High / Low $ 6.95 / 4.52
- Stock P/E N/A
- Book Value 3.13
- EPS -1.91
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.50 %
- 52 Week High 6.95
- 52 Week Low 1.13
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Analyst Target Price
$5.31
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-10 | 2025-08-06 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-08-09 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.49 | -0.37 | -0.37 | -0.67 | -0.6138 | -0.56 | -1.24 | 0.14 | -0.93 | -0.79 | -1.85 | -1.07 |
| Estimated EPS | -0.4796 | -0.53 | -0.54 | -0.6069 | -0.6817 | -0.8708 | -0.84 | -0.77 | -0.92 | -0.91 | -1.04 | -1.02 |
| Surprise | -0.0104 | 0.16 | 0.17 | -0.0631 | 0.0679 | 0.3108 | -0.4 | 0.91 | -0.01 | 0.12 | -0.81 | -0.05 |
| Surprise Percentage | -2.1685% | 30.1887% | 31.4815% | -10.3971% | 9.9604% | 35.6913% | -47.619% | 118.1818% | -1.087% | 13.1868% | -77.8846% | -4.902% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZNTL
2026-04-11 09:35:23
Zentalis Pharmaceuticals has selected a 400mg once-daily regimen for azenosertib as the optimal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer, based on interim analysis from the DENALI Phase 2 trial. This decision is crucial for their potential accelerated approval pathway, aligning both ongoing DENALI and planned ASPENOVA trials. The company's investment narrative heavily relies on azenosertib's success, with a topline readout expected by year-end 2026, though Zentalis remains loss-making with a volatile stock.
2026-04-10 20:39:35
Zentalis Pharmaceuticals saw a 20% stock surge after announcing its WEE1 inhibitor, azenosertib, dose selection for platinum-resistant ovarian cancer, despite prior toxicity challenges and a clinical hold. However, the article suggests that Aprea Therapeutics' WEE1 inhibitor, APR-1051, may have a superior therapeutic profile due to a cleaner safety record, daily dosing, and clinical activity at lower doses, avoiding the off-target toxicity issues faced by Zentalis. The piece implies that while Zentalis has a head start in development, Aprea's approach could ultimately lead to a more dominant market position, drawing parallels to the PARP inhibitor market where therapeutic window was key.
2026-04-10 11:39:35
Guggenheim has increased its price target for Zentalis Pharmaceuticals (NASDAQ:ZNTL) to $10 from $6, maintaining a Buy rating, following the company's decision on the optimal dose for its ovarian cancer treatment. Zentalis announced the selection of a 400mg once-daily monotherapy dose for azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer, based on promising interim data from the DENALI Part 2a study. The company's stock has surged over 290% in the past year, and other analyst firms like H.C. Wainwright, TD Cowen, and Oppenheimer also reiterated positive ratings and price targets.
2026-04-09 21:39:35
Zentalis Pharmaceuticals has selected 400mg QD 5:2 azenosertib monotherapy as the pivotal study dose for Cyclin E1-positive platinum-resistant ovarian cancer, based on interim analysis from the DENALI Part 2a trial. This dose demonstrated a clearly differentiated response rate and comparable safety profile over the 300mg dose. The company is advancing with Phase 2 DENALI and Phase 3 ASPENOVA trials and initiating pre-commercial activities, with topline DENALI Part 2 readout expected by year-end 2026.
2026-04-09 13:10:16
Zentalis Pharmaceuticals has selected a 400mg dose of azenosertib for its DENALI Phase 2 trial and upcoming ASPENOVA Phase 3 study, based on superior response rates and comparable safety seen in interim analysis. The company has expanded the DENALI trial with a new cohort and expects to fund operations into late 2027 with its current cash and securities. Azenosertib is being developed as a potential best-in-class therapy for Cyclin E1-positive platinum-resistant ovarian cancer.
2026-04-09 13:10:16
Zentalis Pharmaceuticals has chosen a 400mg once daily dose of its WEE1 inhibitor azenosertib for its pivotal DENALI Phase 2 and confirmatory ASPENOVA Phase 3 trials in Cyclin E1-positive platinum-resistant ovarian cancer. This decision follows an interim analysis of DENALI Part 2a, which showed a significantly improved response rate at the 400mg dose compared to 300mg, with a comparable safety profile. The company aims to offer a biomarker-driven, oral monotherapy that could provide a more convenient treatment option for patients.
